a year ago

Neupulse Raises $3.2M to Advance Wearable Device for Tourettes Syndrome

  • Neupulse, a UK-based health tech company developing a wearable device for Tourettes Syndrome, has secured $3.2 million in seed funding

  • The round was led by Eos Advisory with participation from US-based investors

  • The funding will be used to advance the device towards commercialization

  • Neupulse's device aims to provide a safe and effective non-drug treatment for Tourettes Syndrome, offering an alternative to current medication and therapy options.

      • ProblemHealthcare

      "Tourette's Syndrome is a debilitating condition that can severely impact quality of life, with current treatment options being limited to medication and cognitive behaviour therapy."

      Solution

      "Neupulse is developing a safe and effective non-drug treatment for Tourette's Syndrome and other tic disorders using a wearable device that gently stimulates the median nerve in the wrist. This technology aims to reduce tics and the urge to tic, offering a potential alternative to existing treatment methods."

      Covered on